A study has found that the common cough medicine ingredient Dextromethorphan may be effective in treating lung fibrosis, a condition caused by excess scarring in the lungs. Lung fibrosis can result from various causes, including exposure to irritants, chemotherapy side effects, and autoimmune diseases. Dextromethorphan was shown to reduce scarring in mouse models of lung fibrosis by impeding collagen formation. The drug is already FDA-approved and widely available. Further research is being conducted to understand how Dextromethorphan works and to potentially develop improved versions for clinical trials in human patients. This discovery offers promising therapeutic potential for a condition with no current cure.
Source link
Dextromethorphan found to have potential in treating lung fibrosis
